Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation
Public Health · 2024
DOI: 10.1016/j.puhe.2024.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health, 2024. Verfasst von Kailu Fang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Inn…. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Mass Screening. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang University, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
OBJECTIVES: China has the largest number of hepatitis C virus (HCV) infection in the world, but current levels of diagnosis and treatment are low. The objective of this study was to assess the cost-effectiveness of various universal HCV screening and treatment strategies in China and inform decisions on health policy. STUDY DESIGN: A cost-effectiveness analytical study. METHODS: We developed a Markov model to investigate cost-effectiveness of different HCV screening and treatment strategies in China. We simulated several screening scenarios for Chinese people aged 18-70 years. We estimated incremental cost-effectiveness ratios (ICERs) of different intervention scenarios compared with status quo. RESULTS: Expanded HCV screening and treatment strategy with prioritisation for high-risk groups (Scenario S5) was the most cost-effective strategy (ICER: USD $11,667.71/quality-adjusted life-year [QALY] gained), which resulted in great reduction in HCV-related diseases and deaths, with a 67.11% reduction in cases of chronic HCV. Universal HCV screening and treatment implementation remains a cost-effective strategy when delayed until 2025 (ICER: USD $17,093.69/QALY), yet the delayed strategy is less effective in reducing HCV-related deaths. CONCLUSIONS: Expanded HCV screening and treatment strategy with prioritisation for high-risk groups is the most cost-effective strategy and has lead to a significant reduction in both HCV morbidity and mortality in China, which would essentially eliminate HCV as a public threat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The…
- Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Förderung
- National Natural Science Foundation of China
- Zhejiang University
- National Major Science and Technology Projects of China
Zitieren
APA
Fang, K., Wang, H. L., Lin, Y., Zheng, L., Li, S., & Wu, J. (2024). Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation. Public Health. https://doi.org/10.1016/j.puhe.2024.01.012
Vancouver
Fang K, Wang HL, Lin Y, Zheng L, Li S, Wu J. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation. Public Health. 2024. doi:10.1016/j.puhe.2024.01.012
BibTeX
@article{Fang2024,
author = {Fang, Kailu and Wang, Hong-Liang and Lin, Yushi and Zheng, Luyan and Li, Shuwen and Wu, Jie},
title = {Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation},
journal = {Public Health},
year = {2024},
doi = {10.1016/j.puhe.2024.01.012}
}
EUVIMED